The four-marker combination for second-trimester quadruple screening is Alpha-Fetoprotein (AFP), Unconjugated Estriol (uE3), Human Chorionic Gonadotropin (hCG), and Inhibin A. In a pregnancy affected by Down syndrome, maternal blood levels of AFP and uE3 are both reduced by roughly 25%, while hCG and Inhibin A concentrations climb to approximately double the normal values. This distinct bidirectional pattern is what allows the test, together with maternal age, to detect about 80% of cases while keeping the false-positive rate near 5%.
The quadruple screen hinges on two analytes that drop and two that rise. Understanding these shifts not only answers the “what” but clarifies why precise immunoassay design and cutoff algorithms must account for the narrow margin between typical and atypical values. For test developers and clinical labs alike, the combination of AFP, uE3, hCG, and Inhibin A—with AFP/uE3 at ~0.75 MoM and hCG/Inhibin A at ~2.0 MoM in Down syndrome—is the non-negotiable core of second-trimester aneuploidy screening.
Why These Four Markers Form the Quadruple Screen
The Dual Suppression Pattern: AFP and uE3
Alpha-Fetoprotein (AFP) is a fetal glycoprotein that normally crosses into maternal serum. In Down syndrome pregnancies, AFP production by the fetal liver is dampened, causing maternal levels to drop to a median of roughly 0.75 multiples of the median (MoM)—a 25% decrease.
Unconjugated Estriol (uE3) follows a similar downward trajectory. This estrogen derivative relies on a functional fetal adrenal–placental axis, which is impaired in trisomy 21. The result is another 25% reduction, with typical values around 0.75 MoM. These decreases are subtle but statistically significant when combined with the elevated markers.
The Dual Elevation Pattern: hCG and Inhibin A
Human Chorionic Gonadotropin (hCG) is the poster child of pregnancy testing, but in the quadruple screen it’s the quantitative shift that matters. In Down syndrome, trophoblast activity is altered, pushing maternal hCG to roughly double the normal median, often reported near 2.0 MoM.
Inhibin A is the fourth pillar. This dimeric glycoprotein, produced by the corpus luteum and placenta, is also over-expressed in trisomy 21 pregnancies. Its concentration rises to a similar 2.0 MoM level, reinforcing the overall risk score.
How the Analyte Shifts Translate Into Detection
The Statistical Muscle Behind the Screen
No single marker is strong enough alone. AFP and uE3 each have limited individual sensitivity for Down syndrome. It’s the combination—using multivariate Gaussian distributions—that lifts detection to the 80% mark at a 5% false-positive threshold.
MoM values are the universal language. By normalizing raw concentrations to gestational-age–specific medians, labs can compare results across populations and instruments. The median shifts cited (0.75 and 2.0 MoM) are what power the likelihood ratio calculations that ultimately stratify risk.
A Critical Contrast: Down Syndrome vs. Trisomy 18
Not all aneuploidies have the same signature. Trisomy 18 (Edwards syndrome) shows a completely different profile: all three core markers (AFP, uE3, hCG) are simultaneously depressed—often with AFP at ~0.65 MoM, uE3 at ~0.43 MoM, and hCG at ~0.36 MoM.
This distinction is essential for multi-analyte immunoassay design. A test kit that conflates the patterns would misclassify pregnancies. The quadruple screen’s algorithm must incorporate separate risk calculations for different aneuploidies, using the specific marker trajectories for each condition.
Understanding the Trade-offs
The Inherent False-Positive Burden
A 5% false-positive rate means 1 in 20 screen-positive results is a normal pregnancy. This leads to unnecessary invasive follow-up procedures, causing anxiety and carrying procedural risks. Pushing detection higher often inflates this rate; relaxing it misses more cases.
Amniocentesis or chorionic villus sampling is the historical next step, but it carries a small risk of pregnancy loss. That’s why the screen’s cutoff is a delicate balance—maximizing detection while minimizing the number of women who undergo invasive testing for a healthy fetus.
Assay Engineering Challenges
Even small analytical imprecision can skew MoM calculations. Since the shifts are modest (25% decrease or 2-fold increase), an immunoassay with poor lot-to-lot reproducibility or cross-reactivity can convert a true risk into a false negative or false positive.
Manufacturers must select highly specific antigens and antibody pairs. For Inhibin A, interference from related inhibin forms can distort results. For hCG, differential recognition of intact vs. beta subunit matters. The primary reference underscores that precision across all four distinct serum proteins is the price of admission for a reliable kit.
The Biological Gray Zone
Marker levels are continuous, not binary. A 0.8 MoM for AFP or a 1.8 MoM for hCG sits in an overlap zone between normal and affected populations. The risk algorithm smooths this with maternal age, but no single result is diagnostic. Counselors must interpret the final ratio in the context of ultrasound findings and other clinical data.
Making the Right Choice for Your Goal
Based on whether you’re interpreting results, developing a test, or setting clinical protocols, the biomarker information takes different forms.
- If your primary focus is interpreting a patient result: Remember that the quadruple screen yields a risk ratio, not a diagnosis. The hallmark Down syndrome pattern is low AFP and uE3 (≈0.75 MoM) plus high hCG and Inhibin A (≈2.0 MoM). Use this to guide conversations about invasive testing options.
- If your primary focus is developing an IVD immunoassay: Your reagent selection must ensure that each of the four analytes—AFP, uE3, hCG, Inhibin A—is measured with high specificity and precision. Any cross-reactivity can warp MoM calculations and compromise the 80% detection rate.
- If your primary focus is optimizing screening algorithms: Integrate the marker patterns for Down syndrome separately from those for Trisomy 18 (low AFP, uE3, and hCG). This prevents misclassification and allows more refined risk stratification, especially when combined with ultrasound indicators like nuchal translucency.
In the end, the quadruple screen’s power lies not in any single analyte but in the coordinated dance of four proteins, each moving in a predictable direction. Mastering that pattern—both in the lab and in the clinic—turns a simple blood draw into a life-shaping decision tool.
Summary Table:
| Biomarker | Down Syndrome (Trisomy 21) | Trisomy 18 (Edwards Syndrome) | Primary Source / Biological Role |
|---|---|---|---|
| AFP | Decreased (~0.75 MoM) | Decreased (~0.65 MoM) | Fetal liver glycoprotein |
| uE3 | Decreased (~0.75 MoM) | Decreased (~0.43 MoM) | Fetal adrenal–placental axis |
| hCG | Increased (~2.0 MoM) | Decreased (~0.36 MoM) | Placental trophoblast activity |
| Inhibin A | Increased (~2.0 MoM) | Variable / Normal | Placenta & corpus luteum |
Develop High-Precision Aneuploidy Screening Assays with CamelBio
Building reliable second-trimester quadruple screening kits requires high-specificity antibodies and antigens to prevent cross-reactivity and lot-to-lot variation.
CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials (AFP, uE3, hCG, Inhibin A), technical services, and assay optimization consulting—covering every stage from initial concept to clinic.
Contact CamelBio today to source high-performance raw materials and enhance your screening assay precision!